Children with History of Lymphoma Prone to Gastrointestinal Problems

According to a new study, children who have been successfully treated for lymphoma or another type of cancer are more likely to develop mild to severe gastrointestinal problems in the future.

In order to come to their conclusions, researchers from the University of California, San Francisco analyzed the gastrointestinal problems of 14,358 patients. These patients, who self-reported the problems, survived at minimum five years of treatment for cancers like lymphoma, leukemia, brain tumors or bone tumors.

The researchers found that over 40 percent of the subjects experienced some sort of gastrointestinal issues within two decades of their treatment, including but not limited to: ulcers, esophageal disease, indigestion, polyps, chronic diarrhea, colitis, gallstones and jaundice.

"While physicians continue to learn about the long-term consequences of pediatric cancer and its therapy, it is essential that we provide comprehensive follow-up care that appropriately addresses the complications cancer survivors may experience," lead study author Dr. Robert Goldsby, pediatric cancer specialist at UCSF Benioff Children's Hospital and director of the UCSF Survivors of Childhood Cancer Program, said in a news release.

"These are serious issues that can have a real impact on a person's quality of life," Goldsby added.

Nevertheless, all of the scientists involved agreed that more research needs to be conducted before any definitive conclusions can be reached from these results.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap